3.97
-0.24 (-5.70%)
Previous Close | 4.21 |
Open | 4.16 |
Volume | 27,226 |
Avg. Volume (3M) | 38,072 |
Market Cap | 3,834,619 |
Price / Sales | 3.88 |
Price / Book | 1.33 |
52 Weeks Range |
Operating Margin (TTM) | -2,151.43% |
Diluted EPS (TTM) | -5.05 |
Quarterly Revenue Growth (YOY) | -79.00% |
Current Ratio (MRQ) | 1.70 |
Operating Cash Flow (TTM) | -4.95 M |
Levered Free Cash Flow (TTM) | -3.00 M |
Return on Assets (TTM) | -100.63% |
Return on Equity (TTM) | -218.77% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Mixed | Bearish |
Medical Devices (Global) | Mixed | Bearish | |
Stock | Tivic Health Systems, Inc. | - | - |
AIStockmoo Score
Analyst Consensus | 0.0 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -2.5 |
Average | -1.13 |
Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body’s own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions. |
|
Sector | Healthcare |
Industry | Medical Devices |
Investment Style | Small Value |
% Held by Insiders | 12.81% |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
10 Sep 2025 | Announcement | Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing |
20 Aug 2025 | Announcement | Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers |
15 Aug 2025 | Announcement | Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025 |
14 Aug 2025 | Announcement | Tivic Reports Second Quarter 2025 Financial Results |
07 Aug 2025 | Announcement | Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast |
08 Jul 2025 | Announcement | Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO |
24 Jun 2025 | Announcement | Tivic Health Announces 2025 Annual Meeting of Stockholders |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |